Brasofensine

DB04857ExperimentalSmall molecule

Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. In November 2001,... In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.

Mechanism: When the neurotransmitter dopamine is released into the synaptic cleft, brasofensine prevents it from entering back into the source nerve cell, thereby allowing a longer period of synaptic activity.
Curator reviewed
Primary indication: For the treatment of Parkinson's Disease.Curator reviewed
Formula / weight: C₁₆H₂₀Cl₂N₂O · 327.25 g/mol (avg)
Code names: BMS-204756 · NS-2214

Resolves to

Compound

UNII1YP2S94RVHCAS171655-91-7ChEMBLCHEMBL2104184PubChem9614919KEGGD03153

Structure

InChIKeyNRLIFEGHTNUYFL-QJDHNRDASA-NSMILES[H][C@@]12CC[C@@]([H])(N1C)[C@]([H])(\C=N\OC)[C@H](C2)C1=CC(Cl)=C(Cl)C=C1

Targets

P31645SLC6A4P14416DRD2

What you can answer from here — as of March 06, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Brasofensine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account